Authors
Latest:
Dr. Smith Discusses CAR T Cell Persistence in MyelomaEric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.
Latest:
Dr. Papa on the Impact of CAR T Cell Trial in Head and Neck CancerSophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses the impact of a recent study of chimeric antigen receptor (CAR) T cells in head and neck squamous cell carcinoma.
Latest:
Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALLLow disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.
Latest:
Integrating Ide-Cel Into Pretreated Multiple Myeloma Regimens: Shaji Kumar, MDThe hematologist from Mayo Clinic discussed the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.
Latest:
Selecting CAR T-Cell Therapies for R/R DLBCLExperts discuss the use and selection of CAR T therapies in relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Bijal Shah, MD, on AUTO1 in R/R B-Cell ALL and the FELIX TrialShah explained that the trial is unique due to its inclusion of patients with MRD–positive B-ALL.
Latest:
Dr. Usmani Discusses CAR T-Cell Therapy in Multiple MyelomaSaad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses CAR T-cell therapy in multiple myeloma.
Latest:
Dr. Bauml on CAR T-Cell Therapy in Head and Neck CancerJoshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses CAR T-cell therapy in head and neck cancer.
Latest:
Speakers Suggest Moving Newer Agents Into Earlier Lines in MMBispecific T-cell engagers and chimeric antigen receptor T-cell therapies seem destined to move into earlier lines of therapy for multiple myeloma (MM), speakers at the European Hematology Association 2021 Virtual Congress said.
Latest:
Dr. Maloney on the Value of CAR T Cells in Relapsed/Refractory Aggressive LymphomasDavid G. Maloney, MD, PhD, discusses the value of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive lymphomas.
Latest:
Dr. Winter on the Promise of CAR T-Cell Therapy in Hematologic MalignanciesJane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.
Latest:
Monitoring and Support for Patients Receiving CAR T-Cell TherapyExperts discuss providing supportive care to patients receiving CAR T-cell therapy.
Latest:
Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALLNaval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia.
Latest:
Dr. Epperla on CAR T-Cell Therapy in MCLNarendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).
Latest:
Dr. Maloney on Targets for CAR T-Cell TherapyDavid Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the success and challenges of chimeric antigen recptor (CAR) T-cell therapy in hematologic malignancies.
Latest:
Dr. Andreadis on CAR T-Cell Therapy in Relapsed/Refractory MCLCharalambos (Babis) Andreadis, MD, MSCE, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.
Latest:
Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.
Latest:
Dr. Coutre Discusses Challenges With CAR T-Cell Therapy in ALLSteven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia.
Latest:
Dr. Perl on Challenges of Implementing Immunotherapy in AMLAlexander E. Perl, MD, MS, discusses the challenges of using immunotherapy with antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies in acute myeloid leukemia.
Latest:
Cilta-Cel Yields High Response Rates in R/R Multiple Myeloma: Saad Z. Usmani, MD, MBA, FACPThe director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed overall response rate and stringent complete responses in the CARTITUDE-1 trial.
Latest:
Characteristics, Healthcare Utilization, and Costs of Medicare Patients Receiving CAR T-Cell TherapyKarl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.
Latest:
Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-CellsThe expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma.
Latest:
Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma CollaborationAmgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Latest:
Dr. Sadelain on CAR T-Cell TherapiesMichel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.
Latest:
June Provides Insight Into Managing AEs From CAR T-Cell TherapiesThough clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy
Latest:
Gene Therapy for Overactive Bladder, Incontinence Shows Good Safety, EfficacyThe locally injected gene therapy product is the subject of an ongoing phase 2a clinical trial.
Latest:
KTE-X19 Safe, Efficacious as Therapy for Pediatric B-Cell ALL in ZUMA-4Results of the phase 1 portion of ZUMA-4 support continued investigation into the efficacy of KTE-X19 in pediatric patients with B-cell acute lymphoblastic leukemia.
Latest:
Dr. D’Angelo on Selecting CAR T-Cell Therapy or Transplantation in DLBCLChristopher R. D’Angelo, MD, discusses factors that determine whether CAR T-cell therapy or autologous stem cell transplant should be used in patients with relapsed/refractory diffuse large B-cell lymphoma.
